{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:11:38Z","timestamp":1780467098714,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA233332"],"award-info":[{"award-number":["CA233332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael W. and Georgia Taylor Michelson"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA251801"],"award-info":[{"award-number":["R01CA251801"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41375-026-02926-1","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:51:24Z","timestamp":1773989484000},"page":"1314-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader"],"prefix":"10.1038","volume":"40","author":[{"given":"Mingma G.","family":"Sherpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-9622","authenticated-orcid":false,"given":"Sutapa","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-4833","authenticated-orcid":false,"given":"Weiguo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather C.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-7251","authenticated-orcid":false,"given":"Zhiquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2926_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"key":"2926_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148\u201367.","journal-title":"Nat Rev Cancer"},{"key":"2926_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.2020006783","volume":"138","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138:1099\u2013109.","journal-title":"Blood"},{"key":"2926_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science. 2024;383:eadi5798.","journal-title":"Science"},{"key":"2926_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2021-147473","volume":"138","author":"DW Robbins","year":"2021","unstructured":"Robbins DW, Noviski M, Rountree R, Tan M, Brathaban N, Ingallinera T, et al. Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies. Blood. 2021;138:2251.","journal-title":"Blood"},{"key":"2926_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, Klomp JE, Stalnecker CA, Bryant KL, Edwards AC, Drizyte-Miller K, et al. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science. 2024;384:eadk0775.","journal-title":"Science"},{"key":"2926_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"D Julio","year":"2020","unstructured":"Julio D, Ferran N, Dolors C, Elias C. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020;105:2205\u201317.","journal-title":"Haematologica"},{"key":"2926_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.1032","volume":"44","author":"V Quesada","year":"2012","unstructured":"Quesada V, Conde L, Villamor N, Ord\u00f3\u00f1ez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44:47\u201352.","journal-title":"Nat Genet"},{"key":"2926_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"TJ Hudson","year":"2010","unstructured":"Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernab\u00e9 RR, et al. International network of cancer genome projects. Nature. 2010;464:993\u20138.","journal-title":"Nature"},{"key":"2926_CR10","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.bneo.2024.100059","volume":"2","author":"OM Depies","year":"2024","unstructured":"Depies OM, Guo Q, Gao Y, Sinha S, Ye Z, Han W, et al. Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia. Blood Neoplasia. 2024;2:100059.","journal-title":"Blood Neoplasia"},{"key":"2926_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00690-w","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang Z, Yan H, Boysen JC, Secreto CR, Tschumper RC, Ali D, et al. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer J. 2022;12:99.","journal-title":"Blood Cancer J"},{"key":"2926_CR12","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2010-02-269894","volume":"116","author":"W Ding","year":"2010","unstructured":"Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984\u201393.","journal-title":"Blood"},{"key":"2926_CR13","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3324\/haematol.2013.098384","volume":"99","author":"P Graham","year":"2014","unstructured":"Graham P, Serge K, Alex A, Natalia S, Andrew JS, Francesco F, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014;99:1138\u201348.","journal-title":"Haematologica"},{"key":"2926_CR14","doi-asserted-by":"publisher","first-page":"jcs235275","DOI":"10.1242\/jcs.235275","volume":"133","author":"DA Gir\u00f3n-P\u00e9rez","year":"2020","unstructured":"Gir\u00f3n-P\u00e9rez DA, Vadillo E, Schnoor M, Santos-Argumedo L. Myo1e modulates the recruitment of activated B cells to inguinal lymph nodes. J Cell Sci. 2020;133:jcs235275.","journal-title":"J Cell Sci"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02926-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02926-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02926-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:43:15Z","timestamp":1780465395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02926-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02926-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NEK: Advisory Board for: AbbVie, AstraZeneca, BeOne, Janssen, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for: AstraZeneca, BMS-Celgene, Dren Bio. Research funding from: AbbVie, Acerta Pharma, AstraZeneca, Genentech, Pharmacyclics\/Jannsen, Merck. All funds are directed to the Mayo Clinic and are not retained personally. SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria have been provided to the institution by Pharmacyclics, Merck, AstraZeneca, Janssen, Beone, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh\u2019s participation in consulting activities\/advisory board meetings and DSMC meetings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}